Fig. 4.
The probability of the occurrence of a molecular relapse, defined by 2 consecutive positive PCR assays for bcr-abl within a 4-week interval in patients after PBSCT or BMT from unrelated donors.
The probability of the occurrence of a molecular relapse, defined by 2 consecutive positive PCR assays for bcr-abl within a 4-week interval in patients after PBSCT or BMT from unrelated donors.
